1
Androgens play an important role in the development and progression of prostate cancer. However, the mechanisms by which androgens influence prostate carcinogenesis is incompletely understood. Elucidating the mechanisms by which androgen signaling modulates prostate carcinogenesis may lead to new approaches for the prevention and/or treatment of prostate cancer.
ELL2 (elongation factor), RNA polymerase 2 (previously called eleven-nineteen-lysine-rich leukemia 2) is encoded by an androgenresponse gene. [2] [3] [4] ELL2 was identified as a homolog of ELL, 5 which was initially discovered based on its fusion to MLL (mixed-lineage leukemia), contributing to the pathogenesis of acute myeloid leukemia. 6, 7 ELL2, along with its other two homologs, ELL and ELL3, can function as an RNA polymerase 2 elongation factor through suppressing transient pulsing of RNA polymerase 2 activity. 8 ELL family proteins are components of the super elongation complex (SEC)
as well as the little elongation complex (LEC) (reviewed in ref. 9 ). ELL proteins are associated with EAF (ELL associated factor) family proteins EAF1 and EAF2. Both ELL and EAF family proteins can be present in the SEC and LEC complexes.
Our recent studies suggest that ELL2 plays an important role in prostate carcinogenesis. ELL2 mRNA expression was downregulated in high Gleason grade prostate cancer specimens. 10 Knockdown of ELL2 by siRNA resulted in increased proliferation, migration, and invasion in prostate cancer cell lines. 4, 10 Furthermore, prostatespecific ELL2 knockout resulted in high-grade murine prostatic intraepithelial neoplasia in the mouse model. 4 Considering the potential role of ELL2 in prostate carcinogenesis, it will be important to elucidate the mechanisms regulating ELL2 protein turnover. ELL2
has previously been shown to be polyubiquitinated by E3 ubiquitin ligase Siah1 in Hela cells. 11 In the present study, we investigate ELL2
protein stability and ubiquitination in prostate cancer cells.
| MATERIALS AND METHODS

| Immunostaining of prostate cancer specimens
Prostate cancer tissues were collected from the Department of Urology at the Affiliated Cancer Hospital of Zhengzhou University. The study was reviewed and approved by institutional ethics committee. The normal prostate controls were collected from patients undergoing total cystectomy. For immunostaining, 5 μm sections of paraffin embedded tissues were de-paraffinized with xylene and endogenous peroxidase activity was quenched using 3% H 2 O 2 in methanol for 30 min in the dark.
Tissue sections were dehydrated through graded alcohols and subjected to antigen retrieval using 10 mM sodium citrate. The slides were then washed with TBST (Tris Borate Saline Tween-20) and blocked with 5%
BSA (Bovine Serum Albumin, Sigma-Aldrich Corp., St. Louis, MO) for 1 h.
Slides were incubated with primary ELL2 antibody (Catalog #A302-505A, Bethyl Laboratories, Inc., Montgomery, TX), 1:500 diluted in TBS.
Slides were then washed for 5 min in TBST and incubated with HRP (Horse Radish Peroxidase) conjugated anti-mouse secondary antibody diluted with TBS for 1 hr. After washing, slides were incubated with DAB (3,3′-diaminobenzidine tetrahydrochloride) (Sigma-Aldrich) and immediately washed under tap water after color development. Slides were then counter stained with hematoxylin and observed under a light microscope (Carl Zeiss, Oberkochen, Germany).
All slides stained with ELL2 antibody were reviewed jointly by two of the authors (TY and ZZ, followed by a second, independent review by another pathologist (Jianbo Zhang, Affiliated Cancer Hospital of Zhengzhou University). ELL2 immunostaining in prostatic glandular cells was analyzed at a final magnification of 200X. The score for the IHC stained positive rate was scaled as (−) for <3%, (+) for 3-25%, (++) for 25-50%, and (+++) for >50% of tumor cells stained.
| Isolation of total RNA and real-time RT-PCR
Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA). RNase-free DNase-treated total RNA was reverse-transcribed with a SuperScript III First-Strand Synthesis System (Promega, Madison, WI) following the manufacturer's instruction for quantitative real-time polymerase chain reaction (qPCR). Real-time RT-PCR was performed using SYBR Green method (Roche, Basel, Switzerland). Gene-specific primers are following: ELL2 forward 5′-CGC TGC CTC ATC TCC TCA GAA ACG-3′ and reverse 5′-TGC   AGG GGG TGG TAG GAG GC-3′, GAPDH forward 5′-GTT GCT GAG   TAT GTC GTG GA-3′ and reverse 5-CGG AGA TGA TGA CCC TTT TG-3′. PCR thermocycling parameters were 95°C for 10 min followed by 40 cycles (95°C for 15 s; 60°C for 5 s; 72°C for 20 s).
Each sample was run in triplicate and was normalized to GAPDH RNA. Relative changes in gene expression were expressed as the fold change using 2-△△Ct method. 12 
| Plasmids and reagents
The full-length ELL2 and ELL2 deletion mutants, ELL2(1-292), ELL2
(293-531), and ELL2(532-640), were generated using PCR and cloned into Flag expression vector (pCMV-3Tag-1A, Agilent Technologies, Santa Clara, CA). The ELL2 substitution mutants, K571R, K584R, and K599R, were generated using a QuickChange II site-directed mutagenesis kit (Catalog #200521, Agilent Technologies). All ELL2 mutant expression vectors were confirmed by DNA sequencing.
Expression vectors for HA-ubiquitin plasmid was a kind gift from Dr
Chunbing Zou from University of Pittsburgh, pCMV-myc-EAF1 and pCMV-myc-EAF2 were cloned as previously described.. 13 All vectors were sequence verified. (50 μg/mL) over a time course of 0 up to 24 h prior to preparation of cell lysates. MG132 (Z-leu-leu-leu-al, C2211) and Cycloheximide (CHX, C7698) were from Sigma-Aldrich.
After various treatment, cell lysates were prepared using RIPA and GAPDH (sc-25778, Santa Cruz Biotechnology) followed by HRP (horseradish peroxidase) labeled secondary antibody (Santa Cruz Biotechnology). Signals were visualized using chemiluminescence (ECL™ Western Blotting Detection Reagents®, GE Healthcare, Pittsburgh, PA) and exposed to X-ray film (Fujifilm, Tokyo, Japan).
| Cell proliferation assay
In brief, C4-2 cells were plated at a density of 3 × 10 
| Cell migration and invasion assay
Transwell migration and Matrigel invasion assays were performed 3 | RESULTS 3.1 | ELL2 protein is downregulated in prostate cancer specimens.
Our previous studies showed that the ELL2 mRNA was downregulated in prostate cancer specimens, particularly in high Gleason grade prostate cancer specimens. 10 ELL2 mutation is not frequent in prostate cancer. 4 However, the protein level of ELL2 was not evaluated previously in human prostate specimens. With a commercially available ELL2 antibody, we conducted immunostaining of ELL2 in a had a statistically significant tendency to co-occur in tumor specimens with ELL2 alteration, while two were mutually exclusive ( Table 2) . None of the identified AR response genes were identified previously as also being regulated by ELL2 4 or EAF2. 15 Interestingly, only SPDEF and TM4SF1 were identified as having a statistically significant tendency to co-occur with EAF2 alteration in prostate cancer specimens (data not shown). These results suggest that several other androgen-responsive genes are altered similarly to ELL2 in prostate cancer, perhaps due in part to the dysregulation of AR activity.
| ELL2 knockdown enhances prostate cancer cell proliferation and motility
Previous studies suggested that siRNA knockdown of ELL2 in prostate cancer cells could increase proliferation in BrdU assay and cell migration in transwell assay. 10 Furthermore, ELL2 knockdown in the murine prostate induced a significant increase in proliferation and in the development of neoplastic lesions. 4 To confirm these findings, we used WST-1 assay to evaluate cell proliferation and transwell Matrigel invasion assay for cell motility. Figure 3 showed that knockdown of ELL2 in C4-2 cells using two independent siRNAs caused increased cell proliferation and invasion. The cell lysates were then isolated for western blot analysis using anti-ELL2 antibody. The Western membrane was re-probed using anti-GAPDH antibody as a loading control. C, Androgen induction of ELL2 protein in C4-2 prostate cancer cells. The experiment was conducted identically as described in panel B Since ELL2 plays an important role in regulating prostate cancer cell growth and motility, its protein level is likely to be regulated.
Understanding the mechanism of regulating ELL2 protein turnover will enhance our understanding of mechanisms leading to ELL2 downregulation in prostate carcinogenesis. We first determined the half-life of ELL2 protein in the presence of protein synthesis inhibitor cycloheximide (CHX) in C4-2 cells. Figure 4A showed that ELL2 protein level were dramatically decreased between 3-4 h after CHX treatment, suggesting that the half-life of ELL2 in C4-2 cells should be less than 4 h. We next tested whether ELL2 turnover was mediated through the proteasome. In Figure 4B , as expected, CHX treatment caused a reduction in ELL2 protein level. In contrast, proteasome inhibitor MG132 enhanced ELL2 protein level. In C4-2 cells treated with R1881, ELL2 protein level in the presence of both CHX and MG132 was higher than its level in the presence of CHX, suggesting that MG132 can inhibit ELL2 degradation in the presence of CHX. This finding was consistent with the finding in Figure 4D , co-transfection of HA-tagged ubiquitin with flag-ELL2 showed that flag-ELL2 can be polyubiquitinated, suggesting that the ubiquitin-proteasome pathway was responsible for ELL2 degradation.
3.5 | Amino acid residues K584 and K599 in ELL2 are important for ELL2 degradation
To identify amino acid residues in ELL2 important for its turnover, we have generated various deletion mutants of ELL2. Figure 5A showed the time courses of three ELL2 deletion mutant protein degradation in the presence of CHX. The half-life of ELL2 (293-531) appeared to be longer than 12 h. In contrast, ELL2 (1-292) and ELL2 (532-64D) had a half-life of less than 4 h. To further define the stability of these ELL2 deletion mutants, a short time course study for the stability of these ELL2 mutants in the presence of CHX was conducted ( Figure 5B ). The half-life of ELL2 (1-292) in the presence of CHX appeared to be around 1 h. In contrast, ELL2 (532-640) was less than one hour. Figure 5C showed an even shorter time course study to determine the stability of ELL2 (532-640) and the result indicated that ELL2 (532-640) had a half-life of about 15 min in the presence of CHX. This observation suggests that ELL2 (532-640) contains amino acid residues for polyubiquitination important for protein turnover. To identify potential ubiquitination sites, we utilized UbiPred to predict potential ubiquitylation sites for ELL2. 16 We have generated three ELL2 mutants with point mutations at the K571, K584, and K599, generating K571R, K584R, and K599R. The ELL2 mutant, K571R
exhibited a half-life less than 6 h, suggesting that K571 may not be an essential site for polyubiquitination. ELL2 mutant K584R was still expressed at high level 12 h after CHX treatment. Similarly, ELL2 mutant K599R was readily detectable even 24 h after CHX treatment. The cells were then cultured for 40 h after the transfection and treated for an additional 16 h with 0 or 10 μM MG132. Flag-ELL2 protein was isolated from the denatured cell lysates using anti-FLAG antibody, followed by immunoblotting using both anti-FLAG and anti-ubiquitin antibodies. The whole cell lysate input was probed using anti-FLAG antibody to determine the expression of flag-ELL2. GAPDH was detected as loading control. Data shown are representative of 3 independent experiments. [Color figure can be viewed at wileyonlinelibrary.com]
These findings suggest that K584 and K599 are important in mediating ELL2 polyubiquitination and degradation.
| EAF2 stabilizes ELL2 and inhibits its polyubiquitination
Since ELL2 is tightly associated with EAF family of proteins including both EAF1 and EAF2, 8 we tested whether the binding of myc-tagged EAF1 or EAF2 could stabilize flag-tagged ELL2. Figure 6A showed that co-transfection of myc-EAF1 or myc-EAF2 could enhance the protein level of flag-ELL2. The level of flag-ELL2 was enhanced by either myc-EAF1 or myc-EAF2 co-transfection. The half-life of flag-ELL2 in the presence of CHX was slightly increased in the presence of myc-EAF1 and significantly increased in the presence of myc-EAF2
( Figure 6A ). Furthermore, in Figure 6B , the presence of either myc-EAF1 or myc-EAF2 significantly inhibited polyubiquitination of flag-ELL2, with myc-EAF2 being more effective.
Knockdown of ELL2 resulted in a decrease in EAF2 protein level in 22Rv1 cells ( Figure 7A ). ELL2 knockdown in C4-2 and LNCaP cells
showed variable results (data not shown). In C4-2 and LNCaP cells which also express EAF2, 17 the expression of EAF2 protein was either decreased upon ELL2 knockdown or unchanged. The variability in EAF2 protein levels in response to ELL2 knockdown observed in C4-2
and LNCaP could be due in part to variability in cell cycle. ELL2 depletion has previously been associated with splicing in plasma cells. 18 AR splice variants have been reported to be frequently observed in castration-resistant prostate cancer. 19 We therefore lesions. 4 Microarray analysis of prostates from these mice identified several differentially expressed genes associated with proliferation, cellular motility, and epithelial and neural differentiation; and many of these genes were also down-regulated or deleted in prostate adenocarcinoma cases. 4 The major signaling pathways altered in the mouse ELL2 knockout prostate are likely conserved and are also involved in ELL2 action in human prostate cancer cell lines. We have previously reported downregulation of ELL2 mRNA in high-Gleason score prostate cancer specimens. 10 The downregulation of ELL2 protein in clinical prostate cancer specimens is consistent with its mRNA downregulation. Thus, one mechanism leading to ELL2 protein downregulation is likely mediated through downregulation of its mRNA. Knockdown of ELL2 in prostate cancer cell lines increased proliferation and cell migration. Cell proliferation was previously reported to be positively correlated with high Gleason score in patients. 20 The downregulation of ELL2 in high Gleason score prostate tumor specimens and increased proliferation in prostate cancer cells treated with ELL2 knockdown suggests that ELL2 can modulate proliferation of prostate epithelial cells.
FIGURE 6
The effect of EAF1 or EAF2 on ELL2 protein turnover and polyubiquitination. A, C4-2 cells were transiently transfected with FLAG-ELL2 expression vector together with empty Myc-vector, Myc-EAF1, or Myc-EAF2 expression vector for 24 h. The transfected cells were then treated with CHX at 50 μg/mL for 0, 6, 12, or 24 h. FLAG ELL2 expression level were determined by immunoblotting using anti-FLAG antibody. GAPDH was probed as a loading control. B, HEK 293 cells were co-transfected with FLAG-ELL2, Myc-EAF1, Myc-EAF2, empty Myc-vector, and/or HA-ubiquitin as indicated. The transfected cells were cultured for 18 h and then treated with 10 μM MG132 for an additional 16 h. The cell lysates were then prepared for immunoprecipitation using anti-FLAG antibody and analyzed by immunoblotting using indicated antibodies. Whole cell lysate input was also analyzed by Western blot using anti-FLAG and anti-Myc antibody. Beta-tubulin was probed as loading control. Data shown are representative of three independent experiments
Our finding that EAF proteins can stabilize ELL2 through blocking its polyubiquitination suggests that loss of EAF proteins could cause downregulation of ELL2. EAF2 was reported as a potential tumor suppressor of prostate cancer and is downregulated frequently in prostate cancer specimens. 17, [21] [22] [23] [24] Also, loss of EAF2 resulted in similar phenotype observed in ELL2 knockout mouse prostate. 4 In C.
elegans model, loss of EAF1 phenocopies the loss of ELL1. 25 It appears that ELL and EAF family proteins require each other for their functions since ELL2 can be stabilized by EAF family proteins. Loss of EAF family proteins in prostate cancer cells can result in destabilization and subsequent functional loss of ELL2. In the prostate, EAF2 appears to play a more important role than EAF1 because EAF2 mRNA is expressed at levels higher than EAF1 mRNA.
Androgens appear to be able to regulate the expression of ELL2 at the both transcriptional and protein stability levels. According to the literature, AR can regulate ELL2 mRNA level in prostate cancer cells. 2, 3 The data from the present study showed that ELL2 protein stability can be enhanced by EAF2 protein, which is also encoded by an androgenresponse gene. Co-induction of EAF2 and ELL2 by androgens can further enhance the ELL2 protein level. This mechanism can amplify the magnitude of androgen induction of ELL2 signaling.
A previous report showed that ELL2 polyubiquitination is mediated through Siah1 E3 ubiquitin ligase. 11 It will be interesting to determine whether Siah1 is also responsible for ELL2 polyubiquitination in prostate cancer cells and whether the mechanism of ELL2 polyubiquitination inhibition by EAF family proteins involves blocking Siah1 access to ELL2.
Our previous studies showed that EAF2 can also undergo polyubiquitination, catalyzed by Siah2 E3 Ligase. Thus, both Siah1
and Siah2 could regulate ELL2 protein, with Siah1 being an ELL2 E3
Ligase directly modulates ELL2 protein turnover and Siah2 being an E3
Ligase for EAF2 and indirectly affects the stability of ELL2. These observations suggest that ELL2 expression can be controlled by multiple mechanisms, including AR regulation of ELL2 transcription, EAF family proteins binding, and Siah1-mediated polyubiquitination.
In summary, this study provided additional evidence for a tumor suppressive role of ELL2 in prostate cancer and suggested that ELL2 is downregulated at the protein level in advanced prostate cancer specimens. This study also identified K584 and K599 are potential ubiquitination sites important for regulating ELL2 stability. EAF family proteins, particularly EAF2, can stabilize ELL2 and block its polyubiquitination. These findings provide a foundation to further explore the mechanisms regulating ELL2 protein level in prostate cancer.
